904 related articles for article (PubMed ID: 8821539)
1. Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues.
Gouardères C; Jhamandas K; Sutak M; Zajac JM
Br J Pharmacol; 1996 Feb; 117(3):493-501. PubMed ID: 8821539
[TBL] [Abstract][Full Text] [Related]
2. Role of adenosine in the spinal antinociceptive and morphine modulatory actions of neuropeptide FF analogs.
Gouardères C; Sutak M; Zajac JM; Jhamandas K
Eur J Pharmacol; 2000 Oct; 406(3):391-401. PubMed ID: 11040346
[TBL] [Abstract][Full Text] [Related]
3. Spinal effect of a neuropeptide FF analogue on hyperalgesia and morphine-induced analgesia in mononeuropathic and diabetic rats.
Courteix C; Coudoré-Civiale MA; Privat AM; Zajac JM; Eschalier A; Fialip J
Br J Pharmacol; 1999 Jul; 127(6):1454-62. PubMed ID: 10455296
[TBL] [Abstract][Full Text] [Related]
4. Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.
Wu HE; Sun HS; Darpolar M; Leitermann RJ; Kampine JP; Tseng LF
J Pharmacol Exp Ther; 2003 Dec; 307(3):1135-41. PubMed ID: 14557378
[TBL] [Abstract][Full Text] [Related]
5. Differential modulation of alpha 2-adrenergic and mu-opioid spinal antinociception by neuropeptide FF.
Kontinen VK; Kalso EA
Peptides; 1995; 16(5):973-7. PubMed ID: 7479344
[TBL] [Abstract][Full Text] [Related]
6. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
7. The neuropeptide FF analogue, 1DMe, reduces in vivo dynorphin release from the rat spinal cord.
Ballet S; Braz J; Mauborgne A; Bourgoin S; Zajac JM; Hamon M; Cesselin F
J Neurochem; 2002 May; 81(3):659-62. PubMed ID: 12065675
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Mjanger E; Yaksh TL
J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
[TBL] [Abstract][Full Text] [Related]
9. Antinociception and delta-1 opioid receptors in the rat spinal cord: studies with intrathecal 7-benzylidenenaltrexone.
Hammond DL; Stewart PE; Littell L
J Pharmacol Exp Ther; 1995 Sep; 274(3):1317-24. PubMed ID: 7562504
[TBL] [Abstract][Full Text] [Related]
10. Further studies of the role of opioid receptors in the nigra in the morphine withdrawal syndrome.
Baumeister AA; Richard AL; Richmond-Landeche L; Hurry MJ; Waguespack AM
Neuropharmacology; 1992 Sep; 31(9):835-41. PubMed ID: 1359441
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive effects of [D-Ala2]deltorphin II, a highly selective delta agonist in vivo.
Qi JA; Mosberg HI; Porreca F
Life Sci; 1990; 47(11):PL43-7. PubMed ID: 2170791
[TBL] [Abstract][Full Text] [Related]
12. Effects of neuropeptide FF analogs on morphine analgesia in the nucleus raphe dorsalis.
Dupouy V; Zajac JM
Regul Pept; 1995 Nov; 59(3):349-56. PubMed ID: 8577940
[TBL] [Abstract][Full Text] [Related]
13. The neuropeptide FF analogue, 1DME, enhances in vivo met-enkephalin release from the rat spinal cord.
Ballet S; Mauborgne A; Gouardères C; Bourgoin AS; Zajac JM; Hamon M; Cesselin F
Neuropharmacology; 1999 Sep; 38(9):1317-24. PubMed ID: 10471085
[TBL] [Abstract][Full Text] [Related]
14. Differential modulation of mu- and delta-opioid antinociception by neuropeptide FF receptors in young mice.
Desprat C; Zajac JM
Neuropeptides; 1997 Feb; 31(1):1-7. PubMed ID: 9574828
[TBL] [Abstract][Full Text] [Related]
15. Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.
Negri L; Improta G; Lattanzi R; Potenza RL; Luchetti F; Melchiorri P
Br J Pharmacol; 1995 Dec; 116(7):2931-8. PubMed ID: 8680727
[TBL] [Abstract][Full Text] [Related]
16. Spinal opioid delta antinociception in the mouse: mediation by a 5'-NTII-sensitive delta receptor subtype.
Mattia A; Farmer SC; Takemori AE; Sultana M; Portoghese PS; Mosberg HI; Bowen WD; Porreca F
J Pharmacol Exp Ther; 1992 Feb; 260(2):518-25. PubMed ID: 1310737
[TBL] [Abstract][Full Text] [Related]
17. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.
Horan PJ; Wild KD; Kazmierski WM; Ferguson R; Hruby VJ; Weber SJ; Davis TP; Fang L; Knapp RJ; Yamamura HI
Eur J Pharmacol; 1993 Mar; 233(1):53-62. PubMed ID: 8386089
[TBL] [Abstract][Full Text] [Related]
18. Evidence for delta opioid receptor subtypes in rat spinal cord: studies with intrathecal naltriben, cyclic[D-Pen2, D-Pen5] enkephalin and [D-Ala2, Glu4]deltorphin.
Stewart PE; Hammond DL
J Pharmacol Exp Ther; 1993 Aug; 266(2):820-8. PubMed ID: 8394918
[TBL] [Abstract][Full Text] [Related]
19. Dissociation of pharmacological pro- and anti-opioid effects by neuropeptide FF analogs.
Quelven I; Roussin A; Burlet-Schiltz O; Gouardères C; Tafani JA; Mazarguil H; Zajac JM
Eur J Pharmacol; 2002 Aug; 449(1-2):91-8. PubMed ID: 12163111
[TBL] [Abstract][Full Text] [Related]
20. Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)TAN-67, in the mouse spinal cord.
Tseng LF; Narita M; Mizoguchi H; Kawai K; Mizusuna A; Kamei J; Suzuki T; Nagase H
J Pharmacol Exp Ther; 1997 Feb; 280(2):600-5. PubMed ID: 9023269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
